LeMaitre Q4 sales $48.9M (+19%), EPS $0.38 (+49%); declares $0.16 dividend, $50M buyback

LEMAITRE VASCULAR INC

2023-FY EPS reported $1.34 revenue$193,484,000

Q4 2023 sales $48.9M (+19% YoY), net income $8.5M (+50%), EPS $0.38 (+49%).
Gross margin 68.1% (+450 bps) driven by ASP increases and manufacturing efficiencies.
Segment highlights: allografts +52%, bovine patches +18%, EMEA sales +21%.
Full year 2024 guidance: sales $209.7-$214.3M (midpoint +10%), EPS $1.60-$1.71.
Board declares $0.16/share dividend (payable Mar 28) and authorizes $50M share buyback.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

LEMAITRE VASCULAR INC reported the quarter ended December 31, 2023 results: revenue $48.9mm, net income $8.5mm, EPS $0.38. Guidance initiated.

Period: the quarter ended December 31, 2023
Revenue: $48.9mm
Net income: $8.5mm
EPS: $0.38
Guidance: initiated
Result: preliminary results

Exact text from the filing

of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results ● Sales $48.9mm, +19% (+14% organic) vs. Q4 2022 ● Gross margin 68.1%, +450 bps ● Op. income $10.2mm, +46% ● Op. margin 21% ● Net income $8.5mm, +50% ● Earnings per diluted share $0.38, +49% ●

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

LEMAITRE VASCULAR INC filing history →

Source: SEC EDGAR

accession 0001437749-24-005732

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.